UnitedHealth Group Incorporated
UNH · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 324.16B | 79.62B | 28.44B | 20.12B | 21.54 |
| 2023 FY | 371.62B | 90.96B | 32.36B | 22.38B | 24.12 |
| 2024 FY | 400.28B | 89.40B | 32.29B | 14.41B | 15.64 |
| 2025 FY | 447.57B | 82.92B | 18.96B | 12.06B | 13.23 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 245.71B | 159.36B | 23.37B | 57.62B | 77.77B |
| 2023 FY | 273.72B | 174.80B | 25.43B | 67.44B | 88.76B |
| 2024 FY | 298.28B | 195.69B | 25.31B | 76.90B | 92.66B |
| 2025 FY | 309.58B | 207.88B | 24.37B | 78.39B | 94.11B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 26.21B | -2.80B | 23.40B | -5.99B | 1.99B |
| 2023 FY | 29.07B | -3.39B | 25.68B | -6.76B | 2.06B |
| 2024 FY | 24.20B | -3.50B | 20.71B | -7.53B | -115.00M |
| 2025 FY | 19.70B | -3.62B | 16.08B | -7.92B | 2.81B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 495.19B | 529.45B | — | — | — |
| 2023 FY | 500.51B | 542.52B | — | — | — |
| 2024 FY | 469.94B | 521.54B | — | — | — |
| 2025 FY | 300.40B | 354.42B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q3 | 113.16B | 20.64B | 4.32B | 2.35B | 2.59 |
| 2025 Q4 | 113.22B | 18.49B | 380.00M | 10.00M | 0.01 |
| 2026 Q1 | 111.72B | 25.41B | 8.99B | 6.28B | 6.90 |
| 2026 Q2 | 112.03B | 36.67B | 7.99B | 5.48B | 6.05 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q3 | 315.27B | 209.46B | 27.21B | 80.14B | 95.79B |
| 2025 Q4 | 309.58B | 207.88B | 24.37B | 78.39B | 94.11B |
| 2026 Q1 | 312.64B | 207.33B | 28.00B | 77.92B | 97.88B |
| 2026 Q2 | 309.73B | 203.78B | 31.47B | 73.33B | 104.51B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q3 | 5.95B | -890.00M | 5.06B | -2.00B | -1.36B |
| 2025 Q4 | 1.11B | -948.00M | 160.00M | -2.00B | 911.00M |
| 2026 Q1 | 8.91B | -763.00M | 8.15B | -2.01B | 3.64B |
| 2026 Q2 | 11.05B | -799.00M | 10.25B | -2.09B | 3.47B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q3 | 313.53B | 366.46B | — | — | — |
| 2025 Q4 | 300.40B | 354.42B | — | — | — |
| 2026 Q1 | 246.24B | 296.15B | — | — | — |
| 2026 Q2 | 376.56B | 418.42B | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-03-31 | — | — | — | — | — |